Safety of current treatment options for NTRK fusion-positive cancers

GLP-1 agonist Liraglutide prevents MK‑801–induced schizophrenia‑like behaviors and BDNF, CREB, p-CREB, Trk-B expressions in the hippocampus and prefrontal cortex in Balb/c mice

(2023) Meltem Donmez Kutlu et al.   BEHAVIOURAL BRAIN RESEARCH

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors

(2023) Yoichi Naito et al.   International Journal of Clinical Oncology

Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.

(2023) Theodore Willis Laetsch et al.   JOURNAL OF CLINICAL ONCOLOGY

44O Comparison of clinical outcomes of patients with infantile fibrosarcoma (IFS) treated with larotrectinib in the SCOUT study versus historical cohort: The EPI-VITRAKVI study

(2023) D. Orbach et al.   ESMO Open

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors

(2022) George D. Demetri et al.   CLINICAL CANCER RESEARCH

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

(2022) Steven G Waguespack et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1 or ALK aberrations (STARTRK-NG)

(2022) Ami V Desai et al.   NEURO-ONCOLOGY

The promise of TRK inhibitors in pediatric cancers with NTRK fusions

(2022) Emily R. Blauel et al.   Cancer Genetics

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance

(2022) Fangfang Liu et al.   Frontiers in Oncology

Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.

(2022) Alexander E. Drilon et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.

(2022) Maciej Jerzy Krzakowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.

(2022) Leo Mascarenhas et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review

(2022) Christine Martineau et al.   SUPPORTIVE CARE IN CANCER

Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib

(2021) Shivaani Kummar et al.   CURRENT PROBLEMS IN CANCER

Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment

(2021) Weijie Chen et al.   World Journal of Surgical Oncology

536P Incidence of fractures in TRK fusion cancer patients treated with larotrectinib

(2021) T.W. Laetsch et al.   ANNALS OF ONCOLOGY

Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST.

(2021) Caicun Zhou et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors.

(2021) Sébastien Perreault et al.   JOURNAL OF CLINICAL ONCOLOGY

First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma.

(2021) Vincent Chung et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

(2021) C. B. Westphalen et al.   npj Precision Oncology

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors

(2021) François Doz et al.   NEURO-ONCOLOGY

NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target

(2020) Alessandro Gambella et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

(2020) David S Hong et al.   LANCET ONCOLOGY

JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions

(2020) T. Yoshino et al.   ANNALS OF ONCOLOGY

Characterization of On-Target Adverse Events Caused by TRK Inhibitor Therapy

(2020) D. Liu et al.   ANNALS OF ONCOLOGY

A phase II study of larotrectinib for children with newly diagnosed solid tumors and relapsed acute leukemias harboring TRK fusions: Children’s Oncology Group study ADVL1823.

(2020) Theodore Willis Laetsch et al.   JOURNAL OF CLINICAL ONCOLOGY

TRK inhibitors: managing on-target toxicities

(2020) J.S.J. Lim et al.   ANNALS OF ONCOLOGY

Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers

(2020) Maria Carter-Febres et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

HGG-01. ENTRECTINIB IN RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS: UPDATED DATA IN CHILDREN AND ADOLESCENTS

(2020) Giles Robinson et al.   NEURO-ONCOLOGY

Larotrectinib in adult patients with solid tumours: a multicentre, open-label, phase I dose-escalation study

(2019) D S Hong et al.   ANNALS OF ONCOLOGY

TRK Inhibitors: Clinical Development of Larotrectinib

(2019) Munveer S. Bhangoo et al.   Current Oncology Reports

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

(2019) Chia-Chi Lin et al.   BRITISH JOURNAL OF CANCER

Casting More Light on Pediatric Fractures

(2019) Laura K. Bachrach   PEDIATRICS

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

(2019) James P. Solomon et al.   MODERN PATHOLOGY

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer

(2019) A Amatu et al.   ANNALS OF ONCOLOGY

No pain, no gain? The effects of pain-promoting neuropeptides and neurotrophins on fracture healing

(2019) Seungyup Sun et al.   BONE

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

(2018) Theodore W Laetsch et al.   LANCET ONCOLOGY

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma

(2018) Hadeel Halalsheh et al.   PEDIATRIC BLOOD & CANCER

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

(2018) Alexander Drilon et al.   Cancer Discovery

NTRK fusion-positive cancers and TRK inhibitor therapy

(2018) Emiliano Cocco et al.   Nature Reviews Clinical Oncology

Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review

(2018) Loay Kassem et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3 –Positive Acute Myeloid Leukemia

(2017) Kristen M. Smith et al.   MOLECULAR CANCER THERAPEUTICS

Infantile NTRK-associated Mesenchymal Tumors

(2017) Jessica L Davis et al.   PEDIATRIC AND DEVELOPMENTAL PATHOLOGY

Targeting TRK family proteins in cancer

(2017) Yekaterina B. Khotskaya et al.   PHARMACOLOGY & THERAPEUTICS

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

(2017) Alexander Drilon et al.   Cancer Discovery

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

(2017) Alexander Drilon et al.   Cancer Discovery

NTRKfusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States

(2016) Manju L. Prasad et al.   CANCER

Preclinical characterization and antitumor efficacy of DS-6051b, a novel, orally available small molecule tyrosine kinase inhibitor of ROS1 and NTRKs

(2016) M. Kiga et al.   EUROPEAN JOURNAL OF CANCER

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

(2016) Maria Menichincheri et al.   JOURNAL OF MEDICINAL CHEMISTRY

Congenital mesoblastic nephroma: a study of 19 cases using immunohistochemistry and ETV6-NTRK3 fusion gene rearrangement

(2016) Dina El Demellawy et al.   PATHOLOGY

Abstract A146: Increase antitumor activity of immunotherapy by blocking colony stimulating factor 1 receptor and tropomyosin receptor kinase

(2016) Stephen Mok et al.   Cancer Immunology Research

Abstract 4529: Pharmacokinetics (PK) of LOXO-101 during the first-in-human Phase I study in patients with advanced solid tumors: Interim update

(2015) Howard A. Burris et al.   CANCER RESEARCH

Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib

(2015) Victor Wong et al.   JNCI-Journal of the National Cancer Institute

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

(2015) R. C. Doebele et al.   Cancer Discovery

Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma

(2015) Parag P. Patwardhan et al.   Oncotarget

Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib

(2015) Victor Wong et al.   JNCI-Journal of the National Cancer Institute

BDNF and its TrkB receptor in human fracture healing

(2014) Olaf Kilian et al.   ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER

Mechanisms of neuroblastoma regression

(2014) Garrett M. Brodeur et al.   Nature Reviews Clinical Oncology

TRKing Down an Old Oncogene in a New Era of Targeted Therapy

(2014) Aria Vaishnavi et al.   Cancer Discovery

The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer

(2013) Justin F. Gainor et al.   Journal of Thoracic Oncology

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

(2013) Aria Vaishnavi et al.   NATURE MEDICINE

Trk B signaling in dopamine 1 receptor neurons regulates food intake and body weight

(2013) Brittany L. Mason et al.   Obesity

Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study

(2011) Jane E. Minturn et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers

(2010) Joseph R. Ghilardi et al.   BONE

The Biology of Neurotrophins, Signalling Pathways, and Functional Peptide Mimetics of Neurotrophins and their Receptors

(2008) Stephen Skaper   CNS & Neurological Disorders-Drug Targets